ATE361935T1 - Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens - Google Patents

Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens

Info

Publication number
ATE361935T1
ATE361935T1 AT99913932T AT99913932T ATE361935T1 AT E361935 T1 ATE361935 T1 AT E361935T1 AT 99913932 T AT99913932 T AT 99913932T AT 99913932 T AT99913932 T AT 99913932T AT E361935 T1 ATE361935 T1 AT E361935T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
prostate
psma
extracellular domain
antibodies
Prior art date
Application number
AT99913932T
Other languages
German (de)
English (en)
Inventor
Gerald Murphy
Alton Boynton
Eric Holmes
William Tino
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Application granted granted Critical
Publication of ATE361935T1 publication Critical patent/ATE361935T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99913932T 1998-03-18 1999-03-18 Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens ATE361935T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/044,668 US6150508A (en) 1996-03-25 1998-03-18 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen

Publications (1)

Publication Number Publication Date
ATE361935T1 true ATE361935T1 (de) 2007-06-15

Family

ID=21933651

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99913932T ATE361935T1 (de) 1998-03-18 1999-03-18 Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens

Country Status (13)

Country Link
US (1) US6150508A (enExample)
EP (2) EP1064303B1 (enExample)
JP (1) JP4229591B2 (enExample)
AT (1) ATE361935T1 (enExample)
AU (1) AU768558B2 (enExample)
CA (1) CA2323096C (enExample)
CY (1) CY1106790T1 (enExample)
DE (1) DE69936049T2 (enExample)
DK (1) DK1064303T3 (enExample)
ES (1) ES2288017T3 (enExample)
IL (2) IL138497A0 (enExample)
PT (1) PT1064303E (enExample)
WO (1) WO1999047554A1 (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7070782B1 (en) * 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US7037647B1 (en) 1995-02-24 2006-05-02 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US20040253246A1 (en) * 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
US6962981B1 (en) * 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1710256A1 (en) * 1999-07-29 2006-10-11 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
ATE342282T1 (de) * 1999-07-29 2006-11-15 Medarex Inc Humane monoklonale antikörper gegen prostata spezifisches membranantigen
US6379550B1 (en) * 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US20020132983A1 (en) * 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
JP4463475B2 (ja) * 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2002096460A1 (en) * 2001-05-30 2002-12-05 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
AU2002305767B2 (en) * 2001-09-20 2008-04-10 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
ES2606537T3 (es) 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
US7399743B2 (en) * 2001-10-26 2008-07-15 The Scripps Research Institute Targeted thrombosis
US20040018519A1 (en) * 2001-11-16 2004-01-29 Wright ,Jr. George L Methods and devices for quantitative detection of prostate specific membrane antigen and other prostatic markers
US20070031438A1 (en) * 2001-12-10 2007-02-08 Junghans Richard P Antibodies as chimeric effector cell receptors against tumor antigens
MXPA04011071A (es) 2002-05-08 2005-07-14 Northwest Biotherapeutics Inc Analisis de calidad para celulas que presentan antigenos.
KR20110025885A (ko) 2002-07-15 2011-03-11 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 포스파티딜에탄올아민에 결합하는 펩타이드, 및 바이러스 감염을 치료하는데 있어서 이의 용도
AU2002364501A1 (en) * 2002-08-30 2004-03-19 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20040136998A1 (en) * 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
DE60323677D1 (de) * 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
EP1587837B1 (en) * 2003-01-28 2012-06-13 Proscan RX Pharma Inc. Epitope sequences for prostate cancer diagnosis and treatment
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2005100404A1 (en) * 2004-04-19 2005-10-27 Proscan Rx Pharma Prostate cancer diagnosis and treatment
MX2007008768A (es) * 2005-01-21 2007-10-19 Genentech Inc Dosificacion fija de anticuerpos her.
WO2006089231A2 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US20090226367A1 (en) * 2005-03-11 2009-09-10 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
CN101141955A (zh) * 2005-04-08 2008-03-12 内尔维阿诺医学科学有限公司 包含被取代的丙烯酰基偏端霉素衍生物以及抑制生长因子或其受体的抗体的抗肿瘤组合
LT5414B (lt) * 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
US7718775B2 (en) * 2005-04-14 2010-05-18 Scinopharm Taiwan, Ltd. Monoclonal antibody with the capability of neutralizing enterovirus type 71 infection
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
BE1017200A3 (nl) * 2006-07-03 2008-04-01 Tekni Plex Europ Nv Filmstructuur met hoge zuurstofbarriere eigenschappen en werkwijze voor het vervaardigen van zulke filmstructuur.
EP2162152A2 (en) * 2007-06-01 2010-03-17 Biogen Idec MA, Inc. Cripto binding molecules
CA2698343C (en) 2007-09-04 2018-06-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
EP2740490A1 (en) 2007-10-03 2014-06-11 Cornell University Treatment of proliferative disorders using antibodies to PSMA
AU2008310908B2 (en) 2007-10-12 2014-01-09 Seagen Inc. Combination therapy with antibody-drug conjugates
US7678581B2 (en) * 2008-01-28 2010-03-16 Clarient, Inc. Correlating chemical and spatial data within pathology samples
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
EP2727606A3 (en) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US8772459B2 (en) 2009-12-02 2014-07-08 Imaginab, Inc. J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
TWI582112B (zh) 2011-04-21 2017-05-11 西雅圖遺傳學公司 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二）
SG194510A1 (en) 2011-04-22 2013-12-30 Emergent Product Dev Seattle Prostate-specific membrane antigen binding proteins and related compositionsand methods
EP2858676B1 (en) 2012-06-07 2019-03-13 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
WO2013188740A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
JP6721507B2 (ja) 2013-12-23 2020-07-15 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ）
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
ES3020458T3 (en) 2015-08-07 2025-05-22 Imaginab Inc Antigen binding constructs to target molecules
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CN105524169A (zh) * 2016-02-03 2016-04-27 南昌大学 一种能特异结合前列腺特异性膜抗原的单域重链抗体
CN105524170A (zh) * 2016-02-03 2016-04-27 南昌大学 能特异结合前列腺特异性膜抗原的纳米抗体
CN105542007A (zh) * 2016-02-03 2016-05-04 南昌大学 一种能特异结合前列腺特异性膜抗原胞外区的单域重链抗体
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
EP3558386A1 (de) 2016-12-21 2019-10-30 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
JP7062901B2 (ja) * 2017-09-22 2022-05-09 東ソー株式会社 目的細胞の検出方法
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
CA3103936A1 (en) 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CA3236930A1 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP1757694A3 (en) * 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5773292A (en) * 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
IL126314A (en) * 1996-03-25 2003-07-31 Northwest Biotherapeutics Inc Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains

Also Published As

Publication number Publication date
IL138497A0 (en) 2001-10-31
DE69936049T2 (de) 2008-01-10
WO1999047554A1 (en) 1999-09-23
ES2288017T3 (es) 2007-12-16
CA2323096A1 (en) 1999-09-23
EP1854808A2 (en) 2007-11-14
AU3189699A (en) 1999-10-11
IL138497A (en) 2007-07-04
JP4229591B2 (ja) 2009-02-25
EP1064303B1 (en) 2007-05-09
JP2002506629A (ja) 2002-03-05
CA2323096C (en) 2004-10-19
DE69936049D1 (de) 2007-06-21
PT1064303E (pt) 2007-08-21
EP1064303A1 (en) 2001-01-03
AU768558B2 (en) 2003-12-18
EP1064303A4 (en) 2005-03-02
EP1854808A3 (en) 2008-02-27
CY1106790T1 (el) 2012-05-23
DK1064303T3 (da) 2007-09-17
US6150508A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
ATE361935T1 (de) Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens
DE69735294D1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
ATE488530T1 (de) Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
NZ337413A (en) Antibodies that bind to Prostate Stem Cell Antigen (PSCA) to treat prostate cancer.
KR970703368A (ko) CD44v6에 대한 모노클로날 항체(Monoclonal antibody active against CD44v6)
DK0552296T3 (da) Monoklonale antistoffer fra mus
ATE343597T1 (de) Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
DE60045870D1 (de) Monoklonaler antikörper, hybridoma, immuntestverfahren und diagnosekit
MX9606584A (es) Biosensores sensibles a masas.
TR199801027T2 (xx) Epitelyom te�his ve tedavisi i�in y�ntem.
EP1007570A4 (en) Monospecific antibody reactive with fibrinogen and fibrinopeptide b
DE69822149D1 (de) Erkennung von tmorspezifische genprodukte
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
ATE532796T1 (de) Immunassays zur spezifischen bestimmung von scca- isoformen
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
DE69610948D1 (de) Immunoenzymatisches konjugat, herstellungsverfahren dafür und verwendungen
MX9704717A (es) Antigeno, anticuerpos y ensayo de diagnostico para la enfermedad de alzheimer.
ATE299739T1 (de) Neurokinin b vorläufer aus menschlicher plazenta
DE60333820D1 (de) Konjugate mit einem für die ed-b-domäne von fibronectin spezifischen antikörper, und deren verwendung zum nachweis und zur behandlung von tumoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1064303

Country of ref document: EP